GLP-1 news, FDA updates, Medicare access, and telehealth safety

A plain-English guide to the Medicare GLP-1 Bridge, $50 monthly access, eligibility caveats, and when cash-pay telehealth may still make sense.

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Here is the patient-facing meaning.

The FDA warned telehealth companies about false or misleading compounded GLP-1 marketing. Here are the red flags to avoid.

Cigna’s employee plan change highlights a broader 2026 trend: employers are questioning how to cover expensive obesity drugs.

High-dose semaglutide changes the conversation around maintenance, plateau management, and how patients compare semaglutide with tirzepatide.

Retatrutide results are raising expectations for next-generation obesity medications, but patients still need careful current-treatment decisions.

A recent analysis offered some reassurance around accidental early exposure, but GLP-1 medications are still generally not recommended during pregnancy.

Oral GLP-1 options are becoming mainstream, but injections remain important for many patients. Compare convenience, cost, and expected outcomes.

Use this checklist to evaluate a GLP-1 telehealth program before entering payment or medical information.

After shortages stabilized, compounded GLP-1 marketing faces more scrutiny. This guide explains what patients should ask.